These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30632978)

  • 1. [Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate].
    Sanzhakov MA; Ipatova OM; Torkhovskaya TI; Tikhonova EG; Medvedeva NV; Zakharova TS; Prozorovskiy VN
    Biomed Khim; 2018 Nov; 64(6):505-510. PubMed ID: 30632978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interaction of rifampicin embedded in phospholipid nanoparticles with blood plasma lipoproteins].
    Sanzhakov MA; Ipatova OM; Prozorovskiĭ VN; Medvedeva NV; Torkhovskaia TI
    Biomed Khim; 2014; 60(3):348-53. PubMed ID: 25019397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug delivery system on the base of phospholipid nanoparticles for rifampicin].
    Sanzhakov MA; Prozorovskiĭ VN; Ipatova OM; Tikhonova EG; Medvedeva NV; Tarkhovskaia TI
    Biomed Khim; 2013; 59(5):585-90. PubMed ID: 24479349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity.
    Carneiro SP; Carvalho KV; de Oliveira Aguiar Soares RD; Carneiro CM; de Andrade MHG; Duarte RS; Dos Santos ODH
    Colloids Surf B Biointerfaces; 2019 Mar; 175():306-313. PubMed ID: 30553206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
    Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
    J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Heinrichs MT; May RJ; Heider F; Reimers T; B Sy SK; Peloquin CA; Derendorf H
    Int J Mycobacteriol; 2018; 7(2):156-161. PubMed ID: 29900893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis.
    Sharma S; Kumar M; Sharma S; Nargotra A; Koul S; Khan IA
    J Antimicrob Chemother; 2010 Aug; 65(8):1694-701. PubMed ID: 20525733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis.
    Siu GK; Zhang Y; Lau TC; Lau RW; Ho PL; Yew WW; Tsui SK; Cheng VC; Yuen KY; Yam WC
    J Antimicrob Chemother; 2011 Apr; 66(4):730-3. PubMed ID: 21393153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.
    Vibe CB; Fenaroli F; Pires D; Wilson SR; Bogoeva V; Kalluru R; Speth M; Anes E; Griffiths G; Hildahl J
    Nanotoxicology; 2016 Aug; 10(6):680-8. PubMed ID: 26573343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
    Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
    J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].
    Truffot-Pernot C; Giroir AM; Maury L; Grosset J
    Rev Mal Respir; 1988; 5(4):401-6. PubMed ID: 2845531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
    Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF
    Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
    Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
    Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
    De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
    J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages.
    Chanwong S; Maneekarn N; Makonkawkeyoon L; Makonkawkeyoon S
    Tuberculosis (Edinb); 2007 Mar; 87(2):130-3. PubMed ID: 16860611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641.
    D'Addio SM; Reddy VM; Liu Y; Sinko PJ; Einck L; Prud'homme RK
    Mol Pharm; 2015 May; 12(5):1554-63. PubMed ID: 25811733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.
    Piddock LJ; Williams KJ; Ricci V
    J Antimicrob Chemother; 2000 Feb; 45(2):159-65. PubMed ID: 10660497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.